期刊文献+

多巴胺与神经退行性疾病研究进展 被引量:10

Research progress of dopamine in neurodegenerative diseases
原文传递
导出
摘要 多巴胺调控人类的情绪和认识能力,包括思想、感觉、理解、推理等,同时,它也在人类的运动功能中发挥重要作用。研究表明多巴胺的合成、储存、释放、降解和重摄取等失衡均与中枢神经系统的多种退行性疾病有密切联系,同时许多治疗疾病的有效药物也围绕多巴胺的研究而产生,如多巴胺替代疗法改善帕金森病的运动症状,多巴胺受体阻断剂可改善舞蹈病的运动症状以及调节多种疾病的精神症状,在临床上都取得了可喜的疗效。然而目前未发现与多巴胺代谢直接相关的基因突变,因此未来需要继续深入研究在神经退行性疾病中造成多巴胺代谢失常的机制,旨在为临床新药物靶点和新治疗手段的研发提供线索。 Dopamine is known to regulate human emotions and cognitive abilities, including thinking, feeling, understanding, reasoning, etc. It also plays an important role in motor fimction. Studies reveal a close relationship between neurodegenerative diseases of the central nervous system and imbalance in dopamine synthesis, storage, release, degradation and reuptake. Furthermore, drugs targeting dopamine system have achieved encouraging efficacy clinically, e.g., dopamine replacement therapy improves motor symptoms of Parkinson's disease patients; dopamine receptor antagonist ameliorates motor symptoms of Huntington's disease patients and modulates a variety of psychiatric symptoms of different diseases. Here, we review the current understanding of dopamine function in 7 neurodegenerative diseases, including Parkinson's disease, Huntington's Disease, Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Frontotemporal Dementia, Multiple Sclerosis, and Prion Disease. Surprisingly, no gene mutation is detected in dopamine metabolism in these diseases. Future mechanistic studies on involvement of dopamine metabolism in neurodegenerative diseases will shed light on clinical drug development and novel alternative therapies.
出处 《生命的化学》 CAS CSCD 2014年第2期184-192,共9页 Chemistry of Life
基金 国家重点基础研究发展计划("973"计划)(2011CB504100) 国家自然科学基金项目(81030062) 北京市属高等学校创新团队建设与教师职业发展计划项目(IDHT20140514)
关键词 神经退行性疾病 多巴胺 替代治疗 neurodegenerative diseases dopamine alternative medicine
  • 相关文献

参考文献66

  • 1贾军,李博,孙作厘,潘艳丽,汪璇,王晓民.电针防治帕金森病的实验研究[J].科技导报,2007,25(23):74-80. 被引量:6
  • 2王晓民.帕金森病神经元损害的分子机制和诊治研究进展[A].见:关新民主编.医用神经生物学[C].北京:人民卫生出版社,2002.484.
  • 3Venda LL, Cragg S J, Buchman VL, et al. alpha- Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci, 2010, 33(12): 559-568.
  • 4Bisaglia M, Tosatto L, Munari F, et al. Dopamine quinones interact with alpha-synuclein to form unstructured adducts. Biochem Biophys Res Commun, 2010, 394(2): 424-428.
  • 5Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol, 2002, 44(3 Suppl 1): S167-174.
  • 6Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov, 2006, 5(10): 845-854.
  • 7Yamamoto M, Schapira AH. Dopamine agonists in Parkinson's disease. Expert Rev Neurother, 2008, 8(4): 671-677.
  • 8Cristian A, Katz M, Cutrone E, et al. Evaluation of acupuncture in the treatment of Parkinson's disease: a double-blind pilot study. Mov Disord, 2005, 20(9): 1185- 1188.
  • 9Eng ML, Lyons KE, Greene MS, et al. Open-label trial regarding the use of acupuncture and yin tui na in Parkinson's disease outpatients: a pilot study on efficacy, tolerability, and quality of life. J Altern Complement Med, 2006, 12(4): 395-399.
  • 10Liang XB, Luo Y, Liu XY, et al. Electro-acupunctureimproves behavior and upregulates GDNF mRNA in MFB transected rats. Neuroreport, 2003, 14(8): 1177- 1181.

二级参考文献296

共引文献73

同被引文献130

引证文献10

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部